TG Therapeutics, Inc. (NASDAQ:TGTX) – Equities research analysts at SunTrust Banks decreased their Q3 2017 earnings estimates for TG Therapeutics in a research report issued on Wednesday. SunTrust Banks analyst Y. Suneja now anticipates that the biopharmaceutical company will post earnings of ($0.46) per share for the quarter, down from their prior forecast of ($0.45). SunTrust Banks also issued estimates for TG Therapeutics’ Q4 2017 earnings at ($0.47) EPS, FY2018 earnings at ($1.75) EPS, FY2019 earnings at ($1.25) EPS, FY2020 earnings at ($0.75) EPS and FY2021 earnings at $0.08 EPS.

A number of other equities analysts have also recently commented on the company. FBR & Co reaffirmed a “buy” rating on shares of TG Therapeutics in a research note on Monday, May 1st. BidaskClub cut TG Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 6th. Jefferies Group LLC started coverage on TG Therapeutics in a research note on Tuesday, April 25th. They issued a “buy” rating and a $23.00 price target on the stock. Zacks Investment Research cut TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 16th. Finally, ValuEngine raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. TG Therapeutics presently has an average rating of “Buy” and an average target price of $23.67.

ILLEGAL ACTIVITY WARNING: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.americanbankingnews.com/2017/08/11/q3-2017-earnings-estimate-for-tg-therapeutics-inc-nasdaqtgtx-issued-by-suntrust-banks.html.

Shares of TG Therapeutics (TGTX) opened at 10.10 on Friday. The company has a 50-day moving average price of $10.95 and a 200 day moving average price of $9.95. TG Therapeutics has a one year low of $4.10 and a one year high of $15.35. The company’s market capitalization is $622.73 million.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.01. TG Therapeutics had a negative return on equity of 162.02% and a negative net margin of 68,806.59%. The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million.

Large investors have recently modified their holdings of the company. FMR LLC raised its stake in shares of TG Therapeutics by 70.2% in the first quarter. FMR LLC now owns 6,451,713 shares of the biopharmaceutical company’s stock worth $75,162,000 after buying an additional 2,660,949 shares in the last quarter. Franklin Resources Inc. raised its stake in TG Therapeutics by 20.6% in the second quarter. Franklin Resources Inc. now owns 2,339,166 shares of the biopharmaceutical company’s stock valued at $23,509,000 after buying an additional 398,916 shares in the last quarter. Vanguard Group Inc. raised its stake in TG Therapeutics by 16.0% in the first quarter. Vanguard Group Inc. now owns 1,790,583 shares of the biopharmaceutical company’s stock valued at $20,860,000 after buying an additional 246,404 shares in the last quarter. Columbus Circle Investors raised its stake in TG Therapeutics by 39.0% in the second quarter. Columbus Circle Investors now owns 1,396,396 shares of the biopharmaceutical company’s stock valued at $14,034,000 after buying an additional 391,975 shares in the last quarter. Finally, Jennison Associates LLC purchased a new stake in TG Therapeutics during the first quarter valued at $16,034,000. Hedge funds and other institutional investors own 45.68% of the company’s stock.

In other news, CFO Sean A. Power sold 59,976 shares of TG Therapeutics stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $11.09, for a total value of $665,133.84. Following the sale, the chief financial officer now directly owns 477,464 shares in the company, valued at approximately $5,295,075.76. The sale was disclosed in a filing with the SEC, which is available through this link. 16.70% of the stock is currently owned by company insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.